Jeta Molecular specializes in advanced molecular diagnostics technologies aimed at improving transplantation medicine. Their flagship product, the QTRACE® Analysis System, is designed for the routine monitoring of recipient-derived white blood cells in peripheral blood and bone marrow, providing high-resolution insights into chimerism levels post-transplantation. The system utilizes a combination of QTRACE® INDEL Monitoring Assays and a RNase P Reference Gene Assay, which together enable precise quantification of minor component DNA. Additionally, the HLA TRACE™ Assays facilitate the early detection of genomic loss of mismatched HLA haplotypes, which is crucial for timely intervention in patients undergoing haploidentical hematopoietic stem cell transplantation (HSCT).

Jeta Molecular also employs Digital PCR (dPCR) technology through their DigitalTRACE™ Monitoring Assays, which enhance sensitivity in detecting low-abundant DNA templates, thereby improving chimerism monitoring accuracy. Their TRACE Analysis™ Software offers customizable features for data analysis, protocol generation, and sample tracking, making it a versatile tool for laboratories. By focusing on early detection of transplant rejection and disease relapse, Jeta Molecular aims to enhance patient care and survival rates, supported by collaborations with experts in the field of transplantation.

Netherlands

Jeta's mission is to improve outcomes for transplant patients by providing the highest quality medical devices available. These tests will provide best in class solutions for post-transplant surveillance of disease relapse, as well as organ and stem cell transplant rejection.

Jeta's systems will enable new applications, lead to improved laboratory workflows, lower per test costs and will ideally translate into better patient care and survival rates

Jeta Molecular

Company Details